Evidence map›Paper›PMID 32123540›Full record

ArticleBioPsychoSocial medicine2020

Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol.

Chisato Ohara, Atsushi Sekiguchi, Shu Takakura, Yuka Endo, Naho Tamura, Hiroe Kikuchi, Kazushi Maruo, Norio Sugawara, Kenji Hatano, Hitomi Kawanishi and 9 more

Open access · goldAbstract read
In one paragraph

Article in BioPsychoSocial medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Chisato Ohara1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.
Atsushi Sekiguchi1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.
Shu Takakura2Department of Psychosomatic Medicine, Kyushu University Hospital, Fukuoka, Japan.
Yuka Endo3Department of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.
Naho Tamura4Department of Psychosomatic Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
Hiroe Kikuchi5Department of Psychosomatic Medicine, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.
Kazushi Maruo6Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Norio Sugawara7Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Japan.
Kenji Hatano8Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Japan.
Hitomi Kawanishi1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.
Misako Funaba1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.
Ayako Sugawara1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.
Nobuhiro Nohara9Department of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Keisuke Kawai4Department of Psychosomatic Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
Shin Fukudo3Department of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.
Nobuyuki Sudo2Department of Psychosomatic Medicine, Kyushu University Hospital, Fukuoka, Japan.
Zafra Cooper11Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT USA.
Kazuhiro Yoshiuchi9Department of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tetsuya Ando1Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553 Japan.ORCID 0000-0003-2643-6067
National Center of Neurology and Psychiatry · JPNational Center for Global Health and Medicine · JPKyushu University Hospital · JPThe University of Tokyo · JPDokkyo Medical University · JPTohoku University · JPTohoku University Hospital · JPUniversity of Tsukuba · JPYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effectiveness of psychotherapeutic interventions for eating disorders (EDs) is widely studied in Europe, North America, and Australia/New Zealand. However, few controlled studies and no randomized controlled trials (RCTs) have been conducted in Japan despite the relatively high prevalence of EDs in the Japanese population. The aim of this study is to evaluate the effect of enhanced cognitive behavior therapy (CBT-E), an evidence-supported ED-focused form of cognitive behavior therapy (CBT), for the treatment of bulimia nervosa (BN) in Japan. METHODS/

designThis multicenter RCT will compare CBT-E with treatment as usual (TAU), which is widely used in Japan. A group of 140 adult outpatients with a Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnosis of BN, ≥18 years of age, a body mass index (BMI) > 17.5 and < 40 kg/m DISCUSSION: This will be the first RCT conducted in Japan to compare CBT-E and TAU for the treatment of BN. If CBT-E is found to be more effective than TAU, then the evidence would support its wider use for patients with BN in Japan. Because it is possible to train therapists who do not possess extensive specialist experience, wider use is also likely to be practically feasible. In addition, demonstrating the effectiveness of CBT-E in Japan would demonstrate that it could be successfully extended to additional world cultures and regions.

trial registrationUMIN, UMIN000031625. Registered 7 Mar 2018.

Indexed as

Bulimia nervosaCognitive behavior therapyEating disorderRandomized controlled trial

Identifiers

PMID32123540
PMCPMC7041176
OpenAlexW3012284847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.